Cargando…
L-type Amino Acid Transporter 1 Utilizing Ferulic Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas Along with Decreased Lipid Peroxidation and Prostaglandin Production
[Image: see text] Oxidative stress and pathological changes of Alzheimer’s disease (AD) overlap with metabolic diseases, such as diabetes mellitus (DM). Therefore, tackling oxidative stress with antioxidants is a compelling drug target against multiple chronic diseases simultaneously. Ferulic acid (...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644403/ https://www.ncbi.nlm.nih.gov/pubmed/36027044 http://dx.doi.org/10.1021/acs.molpharmaceut.2c00328 |
_version_ | 1784826734630141952 |
---|---|
author | Tampio, Janne Markowicz-Piasecka, Magdalena Montaser, Ahmed Rysä, Jaana Kauppinen, Anu Huttunen, Kristiina M. |
author_facet | Tampio, Janne Markowicz-Piasecka, Magdalena Montaser, Ahmed Rysä, Jaana Kauppinen, Anu Huttunen, Kristiina M. |
author_sort | Tampio, Janne |
collection | PubMed |
description | [Image: see text] Oxidative stress and pathological changes of Alzheimer’s disease (AD) overlap with metabolic diseases, such as diabetes mellitus (DM). Therefore, tackling oxidative stress with antioxidants is a compelling drug target against multiple chronic diseases simultaneously. Ferulic acid (FA), a natural antioxidant, has previously been studied as a therapeutic agent against both AD and DM. However, FA suffers from poor bioavailability and delivery. As a solution, we have previously reported about L-type amino acid transporter 1 (LAT1)-utilizing derivatives with increased brain delivery and efficacy. In the present study, we evaluated the pharmacokinetics and antioxidative efficacy of the two derivatives in peripheral mouse tissues. Furthermore, we quantified the LAT1 expression in studied tissues with a targeted proteomics method to verify the transporter expression in mouse tissues. Additionally, the safety of the derivatives was assessed by exploring their effects on hemostasis in human plasma, erythrocytes, and endothelial cells. We found that both derivatives accumulated substantially in the pancreas, with over a 100-times higher area under curve compared to the FA. Supporting the pharmacokinetics, the LAT1 was highly expressed in the mouse pancreas. Treating mice with the LAT1-utilizing derivative of FA lowered malondialdehyde and prostaglandin E(2) production in the pancreas, highlighting its antioxidative efficacy. Additionally, the LAT1-utilizing derivatives were found to be hemocompatible in human plasma and endothelial cells. Since antioxidative derivative 1 was substantially delivered into the pancreas along the previously studied brain, the derivative can be considered as a safe dual-targeting drug candidate in both the pancreas and the brain. |
format | Online Article Text |
id | pubmed-9644403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-96444032022-11-15 L-type Amino Acid Transporter 1 Utilizing Ferulic Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas Along with Decreased Lipid Peroxidation and Prostaglandin Production Tampio, Janne Markowicz-Piasecka, Magdalena Montaser, Ahmed Rysä, Jaana Kauppinen, Anu Huttunen, Kristiina M. Mol Pharm [Image: see text] Oxidative stress and pathological changes of Alzheimer’s disease (AD) overlap with metabolic diseases, such as diabetes mellitus (DM). Therefore, tackling oxidative stress with antioxidants is a compelling drug target against multiple chronic diseases simultaneously. Ferulic acid (FA), a natural antioxidant, has previously been studied as a therapeutic agent against both AD and DM. However, FA suffers from poor bioavailability and delivery. As a solution, we have previously reported about L-type amino acid transporter 1 (LAT1)-utilizing derivatives with increased brain delivery and efficacy. In the present study, we evaluated the pharmacokinetics and antioxidative efficacy of the two derivatives in peripheral mouse tissues. Furthermore, we quantified the LAT1 expression in studied tissues with a targeted proteomics method to verify the transporter expression in mouse tissues. Additionally, the safety of the derivatives was assessed by exploring their effects on hemostasis in human plasma, erythrocytes, and endothelial cells. We found that both derivatives accumulated substantially in the pancreas, with over a 100-times higher area under curve compared to the FA. Supporting the pharmacokinetics, the LAT1 was highly expressed in the mouse pancreas. Treating mice with the LAT1-utilizing derivative of FA lowered malondialdehyde and prostaglandin E(2) production in the pancreas, highlighting its antioxidative efficacy. Additionally, the LAT1-utilizing derivatives were found to be hemocompatible in human plasma and endothelial cells. Since antioxidative derivative 1 was substantially delivered into the pancreas along the previously studied brain, the derivative can be considered as a safe dual-targeting drug candidate in both the pancreas and the brain. American Chemical Society 2022-08-26 2022-11-07 /pmc/articles/PMC9644403/ /pubmed/36027044 http://dx.doi.org/10.1021/acs.molpharmaceut.2c00328 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Tampio, Janne Markowicz-Piasecka, Magdalena Montaser, Ahmed Rysä, Jaana Kauppinen, Anu Huttunen, Kristiina M. L-type Amino Acid Transporter 1 Utilizing Ferulic Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas Along with Decreased Lipid Peroxidation and Prostaglandin Production |
title | L-type
Amino Acid Transporter 1 Utilizing Ferulic
Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas
Along with Decreased Lipid Peroxidation and Prostaglandin Production |
title_full | L-type
Amino Acid Transporter 1 Utilizing Ferulic
Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas
Along with Decreased Lipid Peroxidation and Prostaglandin Production |
title_fullStr | L-type
Amino Acid Transporter 1 Utilizing Ferulic
Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas
Along with Decreased Lipid Peroxidation and Prostaglandin Production |
title_full_unstemmed | L-type
Amino Acid Transporter 1 Utilizing Ferulic
Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas
Along with Decreased Lipid Peroxidation and Prostaglandin Production |
title_short | L-type
Amino Acid Transporter 1 Utilizing Ferulic
Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas
Along with Decreased Lipid Peroxidation and Prostaglandin Production |
title_sort | l-type
amino acid transporter 1 utilizing ferulic
acid derivatives show increased drug delivery in the mouse pancreas
along with decreased lipid peroxidation and prostaglandin production |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644403/ https://www.ncbi.nlm.nih.gov/pubmed/36027044 http://dx.doi.org/10.1021/acs.molpharmaceut.2c00328 |
work_keys_str_mv | AT tampiojanne ltypeaminoacidtransporter1utilizingferulicacidderivativesshowincreaseddrugdeliveryinthemousepancreasalongwithdecreasedlipidperoxidationandprostaglandinproduction AT markowiczpiaseckamagdalena ltypeaminoacidtransporter1utilizingferulicacidderivativesshowincreaseddrugdeliveryinthemousepancreasalongwithdecreasedlipidperoxidationandprostaglandinproduction AT montaserahmed ltypeaminoacidtransporter1utilizingferulicacidderivativesshowincreaseddrugdeliveryinthemousepancreasalongwithdecreasedlipidperoxidationandprostaglandinproduction AT rysajaana ltypeaminoacidtransporter1utilizingferulicacidderivativesshowincreaseddrugdeliveryinthemousepancreasalongwithdecreasedlipidperoxidationandprostaglandinproduction AT kauppinenanu ltypeaminoacidtransporter1utilizingferulicacidderivativesshowincreaseddrugdeliveryinthemousepancreasalongwithdecreasedlipidperoxidationandprostaglandinproduction AT huttunenkristiinam ltypeaminoacidtransporter1utilizingferulicacidderivativesshowincreaseddrugdeliveryinthemousepancreasalongwithdecreasedlipidperoxidationandprostaglandinproduction |